Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Hoilund-Carlsen PF, Alavi A. J Alzheimers Dis 2021;84:1457-1460.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hoilund-Carlsen PF, Alavi A. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. J Alzheimers Dis 2021;84:1457-1460.
PMID: 34657891